

# Stephen Madden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2628771/publications.pdf>

Version: 2024-02-01

15  
papers

372  
citations

933447

10  
h-index

1058476

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

675  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. <i>Kidney International</i> , 2004, 65, 904-917.	5.2	75
2	Repuncturing the Renal Biopsy: Strategies for Molecular Diagnosis in Nephrology. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1961-1972.	6.1	54
3	Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. <i>Cancer Letters</i> , 2018, 414, 99-106.	7.2	48
4	Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 717-727.	2.5	35
5	Neuromedin U: A Candidate Biomarker and Therapeutic Target to Predict and Overcome Resistance to HER-Tyrosine Kinase Inhibitors. <i>Cancer Research</i> , 2014, 74, 3821-3833.	0.9	34
6	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.	6.3	32
7	Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 184.	4.4	21
8	TGF $\beta$ <sup>2</sup> and CCN2/CTGF mediate actin related gene expression by differential E2F1/CREB activation. <i>BMC Genomics</i> , 2013, 14, 525.	2.8	14
9	Subunits of BK channels promote breast cancer development and modulate responses to endocrine treatment in preclinical models. <i>British Journal of Pharmacology</i> , 2022, 179, 2906-2924.	5.4	14
10	Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples. <i>Journal of Translational Medicine</i> , 2020, 18, 99.	4.4	12
11	Frequency, impact and a preclinical study of novel <i>ERBB</i> gene family mutations in HER2-positive breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877829.	3.2	11
12	Germline single nucleotide polymorphisms in <i>ERBB3</i> and <i>BARD1</i> genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH). <i>PLoS ONE</i> , 2018, 13, e0200996.	2.5	10
13	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. <i>BMC Medicine</i> , 2020, 18, 349.	5.5	8
14	Prevalence of tumor <i>BRCA1</i> and <i>BRCA2</i> dysfunction in unselected patients with ovarian cancer. <i>Obstetrics and Gynecology Science</i> , 2020, 63, 643-654.	1.6	4
15	<i>Fusobacterium nucleatum</i> : caution with interpreting historical patient sample cohort. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 415-418.	1.1	0